Radiation Oncology Department, Hospital de la Santa Creu i Sant Pau, IIB Sant Pau, Universitat Autònoma de Barcelona, Spain.
Clin Transl Oncol. 2011 Dec;13(12):855-61. doi: 10.1007/s12094-011-0746-2.
Management of muscle-invasive bladder cancer (MIBC) has changed little in the last twenty years. The gold standard treatment is still cystectomy, but it has a significant negative impact on quality of life. Bladder-preservation strategies can be used in some cases but patient selection for this approach remains unclear. New chemotherapy and biologic agents in combination with surgery or radiotherapy could improve results and these possibilities are currently under investigation.
在过去的二十年中，肌层浸润性膀胱癌（MIBC）的治疗方法变化不大。金标准治疗仍然是膀胱切除术，但它对生活质量有显著的负面影响。在某些情况下可以使用保膀胱策略，但这种方法的患者选择仍然不清楚。新的化疗和生物制剂与手术或放疗联合使用可能会改善结果，目前正在对此进行研究。
